Stockscreener 앱 받기
0.2857
1.72%
-0.005
시간 외 거래:
.28
-0.0057
-2.00%
전일 마감가:
$0.2907
열려 있는:
$0.2886
하루 거래량:
607.96K
Relative Volume:
0.29
시가총액:
$25.53M
수익:
-
순이익/손실:
$-166.14M
주가수익비율:
-0.1488
EPS:
-1.92
순현금흐름:
$-139.92M
1주 성능:
-8.63%
1개월 성능:
-74.26%
6개월 성능:
-61.77%
1년 성능:
-77.85%
1일 변동 폭
$0.2812
$0.2931
1주일 범위
$0.2812
$0.3253
52주 변동 폭
$0.228
$1.69
Allakos Inc Stock (ALLK) Company Profile
명칭
Allakos Inc
전화
650-597-5002
주소
825 INDUSTRIAL ROAD, SAN CARLOS, CA
ALLK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
0.2857 | 25.53M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-01-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-18 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-08 | 재개 | Jefferies | Buy |
| 2023-09-27 | 개시 | JMP Securities | Mkt Outperform |
| 2023-05-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-07 | 개시 | Piper Sandler | Overweight |
| 2022-09-12 | 다운그레이드 | SMBC Nikko | Neutral → Underperform |
| 2021-12-22 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-22 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-12-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-12-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-07-15 | 개시 | Cowen | Outperform |
| 2021-05-18 | 개시 | H.C. Wainwright | Buy |
| 2021-02-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-15 | 개시 | BofA Securities | Buy |
| 2020-12-21 | 개시 | SVB Leerink | Outperform |
| 2020-02-27 | 개시 | Barclays | Underweight |
| 2020-02-04 | 재개 | Goldman | Neutral |
| 2018-08-13 | 개시 | Goldman | Neutral |
| 2018-08-13 | 개시 | Jefferies | Buy |
| 2018-08-13 | 개시 | William Blair | Outperform |
모두보기
Allakos Inc 주식(ALLK)의 최신 뉴스
Lee joins Lycia as CMO - BioCentury
It is Poised to be a Bull Market for Allakos Inc (ALLK) - SETE News
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - EIN News
Introducing Our Rant Against Allakos Inc - US Post News
FY2024 EPS Estimates for Allakos Lowered by Leerink Partnrs - Defense World
Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily
This Week’s 14.26% Gain In Allakos Inc (NASDAQ: ALLK) Taught Us Something New - Marketing Sentinel
Evaluating Allakos: Strategic Review, NOL Potential, and Kevin Tang's Activist Stake Amidst Biopharma Challenges - Smartkarma
What To Expect From Eli Lilly’s (LLY) Q4 Earnings - The Globe and Mail
Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR
Such Is The Power Of Allakos Inc (NASDAQ: ALLK) - Stocks Register
Allakos Inc: -85.21% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
Allakos stock tanks after company announces mass layoffs - MSN
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc - GuruFocus.com
The time has not yet come to remove your chips from the table: Allakos Inc (ALLK) - SETE News
Allakos stock plunges to 52-week low of $0.23 amid steep annual decline - Investing.com
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga
Allakos stock tumbles following AK006 trial discontinuation - MSN
Bay Area biotech firm guts staff, shuts trial after dangerous side effects - SFGATE
Allakos plunges 75% on phase 1 data for urticaria asset - MSN
Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp - Defense World
Allakos (NASDAQ:ALLK) Cut to Hold at Piper Sandler - Defense World
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade - MSN
BioAge drops obesity drug; Akero, 89bio cash in on MASH data - BioPharma Dive
Allakos to cease AK006 development after trial setback - MSN
Allakos cuts 75% of workforce after chronic hives trial failure - Clinical Trials Arena
Bay Area biotech firm Allakos suddenly on brink of collapse after trial flops - MSN
Allakos stock hits 52-week low at $0.3 amid market challenges - Investing.com Canada
Allakos shares fall as Jefferies cuts price target to $0.40 By Investing.com - Investing.com Nigeria
Allakos decimated as Phase I Trial of AK006 fails - The Pharma Letter
Allakos shares fall as Jefferies cuts price target to $0.40 - MSN
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds - The Business Journals
Bay Area biotech firm suddenly on brink of collapse after trial flops - SFGATE
Allakos Restructures Amid AK006 Program Discontinuation - TipRanks
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga
Stock market news: Planet Image International surged by 160.47% while Allakos is still declining by 80.30% during mid day trading - Business Upturn
Allakos Inc. (ALLK) PT Lowered to $0.40 at Jefferies - StreetInsider.com
Dow Edges Higher; AT&T Posts Upbeat Earnings - Benzinga
Allakos Shares Plummet to All-Time Low After Lead Candidate Failure - MarketWatch
Stock market today: Allakos dropped by 76.37% whereas Onconetix jumped by 77.10% in early trading - Business Upturn
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Benzinga
Allakos Inc (ALLK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):